Century Therapeutics Files Amended Financials
Ticker: IPSC · Form: 8-K/A · Filed: Jun 26, 2024 · CIK: 1850119
Sentiment: neutral
Topics: amendment, financial-statements, exhibit
TL;DR
Century Therapeutics just filed amended financials for Clade, including audited and pro forma statements for year-end 2023.
AI Summary
Century Therapeutics, Inc. filed an amendment (8-K/A) on June 26, 2024, to include audited financial statements for Clade as of December 31, 2023, and unaudited pro forma condensed combined financial statements for the same period. These financial statements are incorporated by reference as Exhibits 99.1 and 99.2.
Why It Matters
This filing provides updated financial statements, which are crucial for investors to assess the company's financial health and performance following a significant event like a combination.
Risk Assessment
Risk Level: low — This is an amendment to file previously disclosed financial information, not a new material event.
Key Players & Entities
- Century Therapeutics, Inc. (company) — Registrant
- Clade (company) — Subject of financial statements
- December 31, 2023 (date) — Fiscal year end for financial statements
- April 11, 2024 (date) — Earliest event reported date
- June 26, 2024 (date) — Filing date of the amendment
FAQ
What is the purpose of this 8-K/A filing?
The purpose is to amend a previous filing to include audited financial statements of Clade as of and for the year ended December 31, 2023, and unaudited pro forma condensed combined financial statements for the year ended December 31, 2023.
When were the financial statements for Clade prepared?
The audited financial statements are as of and for the year ended December 31, 2023, and the unaudited pro forma condensed combined financial statements are for the year ended December 31, 2023.
What exhibits are being filed with this amendment?
Exhibit 99.1 contains the audited financial statements of Clade, and Exhibit 99.2 contains the unaudited pro forma condensed combined financial statements.
What is the earliest event date reported in this filing?
The earliest event date reported is April 11, 2024.
What is the filing date of this amendment?
This amendment was filed on June 26, 2024.
Filing Stats: 793 words · 3 min read · ~3 pages · Grade level 10.3 · Accepted 2024-06-26 16:47:40
Key Financial Figures
- $0.0001 — ch Registered Common Stock, par value $0.0001 per share IPSC Nasdaq Global Select
Filing Documents
- tm2418216d1_8ka.htm (8-K/A) — 32KB
- tm2418216d1_ex23-1.htm (EX-23.1) — 4KB
- tm2418216d1_ex99-1.htm (EX-99.1) — 347KB
- tm2418216d1_ex99-2.htm (EX-99.2) — 153KB
- image_003.jpg (GRAPHIC) — 3KB
- image_004.jpg (GRAPHIC) — 2KB
- tm2418216d1_ex23-1img001.jpg (GRAPHIC) — 9KB
- 0001104659-24-075201.txt ( ) — 797KB
- ipsc-20240411.xsd (EX-101.SCH) — 3KB
- ipsc-20240411_lab.xml (EX-101.LAB) — 33KB
- ipsc-20240411_pre.xml (EX-101.PRE) — 22KB
- tm2418216d1_8ka_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits (a) Financial statements of businesses acquired. The audited financial statements of Clade as of and for the year ended December 31, 2023 are filed with this Current Report on Form 8-K/A as Exhibit 99.1 and incorporated herein. (b) Pro forma financial information. The unaudited pro forma condensed combined financial statements for the year ended December 31, 2023 are filed with this Current Report on Form 8-K/A as Exhibit 99.2 and incorporated herein. (d) Exhibits Exhibit No. Document 23.1 Consent of Independent Registered Public Accounting Firm. 99.1 Audited Financial Statements of Clade Therapeutics, Inc. for the year ended December 31, 2023. 99.2 Unaudited Pro Forma Condensed Combined Financial Statements for the year ended December 31, 2023. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CENTURY THERAPEUTICS, INC. By: /s/ Brent Pfeiffenberger, Pharm.D. Name: Brent Pfeiffenberger, Pharm.D. Title: President and Chief Executive Officer Date: June 26, 2024